EPCORE DLBCL-3: A phase 3 trial of epcoritamab with or without lenalidomide in patients with diffuse large B-cell lymphoma

This trial is testing the medication epcoritamab when given with or without the medication lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) which is previously untreated.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05660967

Trial aim and background  

The aim of this trial is to find out our effective epcoritamab is for treating elderly patients with DLBCL who are unable to tolerate anthracyclines such as doxorubicin. 

Epcoritamab, also known as EPKINLY, is an antibody that will be given in an injection under the skin (subcutaneously). 
Participants will be split into two groups, one will receive epcoritamab on its own, and the other will receive it along with lenalidomide. This is given as a tablet. People will not be able to choose which group they are in and will be allocated randomly.

Who can enter

People with DLBCL who are unable to have anthracyclines because they are over the age of 80, or over the age of 75 with other conditions which affect their eligibility, may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • Churchill Hospital, London
  • Derriford Hospital, Plymouth
  • Southampton General Hospital, Southampton
  • Royal Cornwall Hospital, Truro

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05660967

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.